Episode 57: Live from Day 1 at ECTRIMS 2018
RealTalk MS10 Okt 2018

Episode 57: Live from Day 1 at ECTRIMS 2018

Greetings from Day 1 at ECTRIMS in Berlin! Today, we're talking about pharmaceutical company Novartis seeking approval from the U.S. Food & Drug Administration and the European Medicines Agency for siponimod, a once-daily oral medication that significantly reduces disability progression for people living with secondary progressive MS.

This is important news, as 80% of the people living with relapsing remitting MS are eventually diagnosed with secondary progressive MS. And currently, there is no approved disease modifying therapy for secondary progressive MS. The FDA has fast-tracked the approval process, and siponimod could gain the necessary regulatory approval in the U.S. by March, 2019, and in Europe by the end of 2019. The day at ECTRIMS started with a "Welcome" session. Imagine a room that has seating for thousands of people, a stage that must have been 30 yards wide, and not one -- not two -- but SIX jumbo screens set up so that everyone in the room could see. And even with that enormous capacity, there were people standing in the aisles to be a part of the initial session. The "Welcome" session featured a short address by the Chair of the ECTRIMS 2018 conference, Professor Reinhard Hohfeld. After the session ended, Professor Hohfeld and I snuck out to the hallway for a quick conversation. You'll hear my exclusive conversation with ECTRIMS Chair Professor Reinhard Hohfeld in today's podcast episode. Be sure to download the special ECTRIMS episodes of RealTalk MS tomorrow and Friday, as well! We have a lot to talk about!! ___________

LINKS
If your podcast app doesn't show these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Download the RealTalk MS App for iOS

Download the RealTalk MS App for Android

Novartis files for FDA & EMA Approval of Siponimod

ECTRIMS 2018

Give RealTalk MS a Rating & Review

___________

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 57
Hosted By: Jon Strum
Guest: Professor Reinhard Hohfeld

Tags: MS, MultipleSclerosis, ECTRIMS2018, Siponimod, RealTalkMS

Episoder(502)

Episode 448: At the National MS Society's Public Policy Conference with David, Cliff, and Michelle

Episode 448: At the National MS Society's Public Policy Conference with David, Cliff, and Michelle

Last week, about 170 MS activists from across the country gathered in Washington, D.C. to participate in the National MS Society's Public Policy Conference. It's hard to come away from this event and ...

30 Mar 31min

Episode 447: Walking with Many Sisters Toward a Cure with Brigitte Delaney

Episode 447: Walking with Many Sisters Toward a Cure with Brigitte Delaney

In 1988, there were just 42 Walk MS events, raising approximately $4 million. In 2025, there were 170 events across the country that raised over $30 million. As the largest private funder of MS resear...

23 Mar 23min

Episode 446: MS Advocacy and the National MS Society's Public Policy Conference with Steffany Stern

Episode 446: MS Advocacy and the National MS Society's Public Policy Conference with Steffany Stern

175 MS activists are heading to Washington, D.C. next week for the National MS Society's Public Policy Conference. Their mission: to bring the concerns of the MS community directly to lawmakers on Cap...

16 Mar 34min

Episode 445: It's MS Awareness Week with Kristine Werner Ozug and Kim, Kim, and Kim

Episode 445: It's MS Awareness Week with Kristine Werner Ozug and Kim, Kim, and Kim

It's MS Awareness Week, and this year we're diving into a theme that hits home for millions: Unseen MS. Multiple sclerosis is a master of disguise; it can be entirely invisible to the naked eye while ...

9 Mar 40min

Episode 444: Treating MS with a GLP-1 with Dr. Ellen Mowry

Episode 444: Treating MS with a GLP-1 with Dr. Ellen Mowry

You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes a...

2 Mar 31min

Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

Welcome back to the third and final part of our coverage of the 2026 ACTRIMS Forum. This week's episode bridges the gap between groundbreaking clinical research and the nuanced reality of living with ...

23 Feb 35min

Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest...

16 Feb 44min

Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the A...

9 Feb 33min

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
hvordan-har-du-det-mann
psykodrama
leger-om-livet
rss-garne-damer
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
foreldreradet
rss-lopedrommen
morten-ramm-lar-kakla-ga-til-du-sovner
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
klimaks
hjernesterk
rss-lev-vel
sinnsyn
hormonelle-frida
rss-kunsten-a-leve
g-punktet
helsetipspodden